BioSpace News Archive

Crossject, a specialty pharma company developing needle-free auto-injectors for emergency situations, will hold a presentation at the Biotech Showcase conference, being held in San Francisco, on January 9, 2024 at 16:30 PT.

Marius Pharmaceuticals, a pharmaceutical company focused on developing innovative therapies for testosterone deficiency, today announced it has initiated a pilot study to better understand the effect of oral testosterone replacement therapy, KYZATREX® (testosterone undecanoate), on spermatogenesis in adult males.

Biomea Fusion, Inc. (Nasdaq: BMEA) today announced that Thomas Butler, Biomea Fusion’s Chief Executive Officer and Chairman of the Board, will present recent clinical progress and 2024 corporate milestones at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 from 8:15 am – 8:55 am PST.

Neurolief, a global leader in medical devices delivering groundbreaking neurotechnology innovations for the treatment of Neurological and Neuropsychiatric disorders, announces the approval of its neuromodulation device, Relivion®, by the Japanese Ministry of Health, Labor and Welfare (MHLW).

Lynx.MD, a leading medical data intelligence platform, announced a new partnership with Allied Digestive Health (ADH), a company of Assured Healthcare Partners (AHP).

Teva Pharmaceutical Industries Ltd. announced the successful completion of the enrollment in the EU and US of the anticipated 640 participants of the ongoing Phase 3 clinical trial of mdc-TJK (TEV-44749) at the J.P. Morgan Healthcare Conference.

Omnia Medical announced that the Patent Trial and Appeal Board of the US Patent and Trademark Office on Thursday September 20th granted institution in IPR2023-00625.

Nyxoah SA announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2023.

C4 Therapeutics, Inc. announced 2024 priorities to execute against its strategic plan to leverage the benefits of targeted protein degradation across drug discovery and clinical development to create and deliver breakthrough therapies for patients.

Catalyst Pharmaceuticals, Inc. reported that it has closed its underwritten public offering of shares of its common stock.